In line with this, the CMS classification reports that hypermutated CMS1 is characterized by MAPK activation while non-hypermutated CRC tumors, englobed into CMS2 subtype, present activating KRAS and PKI3CA mutations [10]. Here, KRAS is linked to colorectal carcinoma.